Nanobiotix Revenue and Competitors
Estimated Revenue & Valuation
- Nanobiotix's estimated annual revenue is currently $2.4M per year.
- Nanobiotix's estimated revenue per employee is $16,879
- Nanobiotix's current valuation is $328.2M. (January 2022)
Employee Data
- Nanobiotix has 141 Employees.
- Nanobiotix grew their employee count by 8% last year.
Nanobiotix's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO & Founder | Reveal Email/Phone |
2 | CEO Nanobiotix USA & EVP Business Development | Reveal Email/Phone |
3 | Chief Staff | Reveal Email/Phone |
4 | VP, Strategic Partnership, Qualified Person | Reveal Email/Phone |
5 | Head Corporate Development, Strategy and New Ventures | Reveal Email/Phone |
6 | Head Transformation | Reveal Email/Phone |
7 | Head HR US & Global Head Talent Management | Reveal Email/Phone |
8 | VP, Global Head Clinical Operations | Reveal Email/Phone |
9 | VP, Strategic Marketing and Corporate Communication | Reveal Email/Phone |
10 | VP, Global Head Clinical Operations | Reveal Email/Phone |
Nanobiotix Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.2M | 27 | N/A | N/A | N/A |
What Is Nanobiotix?
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges. Nanobiotix's novel first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix's Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company's headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.
keywords:N/AN/A
Total Funding
141
Number of Employees
$2.4M
Revenue (est)
8%
Employee Growth %
$328.2M
Valuation
N/A
Accelerator
Nanobiotix News
This oncology platform from Nanobiotix is based on inorganic crystalline hafnium oxide (HfO2) nanoparticles with a diameter of 50 nanometers.
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment...
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $22.5M | 141 | 8% | N/A |
#2 | $15M | 141 | -2% | N/A |
#3 | $20.2M | 141 | 74% | N/A |
#4 | $38.8M | 141 | 5% | N/A |
#5 | $41.9M | 141 | 18% | N/A |